Ahmad Tarhini, MD, PhD, discusses inherited genetic variations and genetic ancestry, particularly for patients with high-risk melanoma.

Panelists discuss how Janus kinase (JAK) inhibitors like pacritinib offer crucial treatment options for myelofibrosis patients with severe thrombocytopenia (platelet counts <50,000 ), highlighting its ...

Phase 1b Beamion LUNG-1 trial data at AACR 2025 showed zongertinib yielded responses in pretreated HER2-mutant NSCLC, ...

Runimotamab plus trastuzumab resulted in positive clinical activity and tolerability over runimotamab alone in patients with ...

Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety ...

Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

Data from the phase 3 BOND-003 trial (NCT04452591), presented at the 2025 American Urological Association Annual Meeting, demonstrated that intravesical cretostimogene grenadenorepvec (CG0070) is a ...

Cretostimogene grenadenorepvec is an investigational oncolytic immunotherapy that is being studied for the treatment of bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC) that is ...

The key takeaways are that prostate cancer misinformation is widespread across online platforms and spans many different ...

A panelist discusses how strategies such as clear patient education, simplified skin care regimens, personalized ...

A panelist discusses how the MARIPOSA, SKIPPirr, and COCOON studies highlight the significant overall survival benefit of the ...

Phase 2b SunRISe-1 data showed TAR-200 monotherapy achieved an 82.4% complete response rate in BCG-unresponsive, high-risk ...